Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database.
Nicolas H ThurinMagali RouyerJérémy JovéMarine Gross-GoupilThibaud HaaserXavier RébillardMichel SouliéGérard de PouvourvilleCamille CaponeMarie-Laure BazilFatiha MessaoudiStéphanie LamarqueEmmanuelle BignonCécile Droz-PerroteauNicholas MoorePatrick BlinPublished in: Expert review of clinical pharmacology (2022)
The findings underline the interest of oral abiraterone acetate over intravenous docetaxel as the first-line treatment option in mCRPC.